CAS: 203120-46-1; (2R,3R,4S)-3-Acetamido-4-Guanidino-2-((1R,2R)-2-Hydroxy-1-Methoxy-3-(Octanoyloxy)Propyl)-3,4-Dihydro-2H-Pyran-6-Carboxylic Acid

该化合物是主要用于治疗流感的一种抗病毒化合物,是一种拉尼尼米病毒的药物,这意味着它会转化成体内的活性形态.这种复合物具有奈拉米丁酶抑制剂的典型特征,它通过阻塞对受感染细胞释放新病毒粒子负责的病毒酶而发挥作用,从而限制病毒的传播.拉尼尼尼米耶尔辛诺酸酯以其长的半衰期著称,它允许与其他抗病毒药物相比,减少剂量的频率.它通过吸入来进行,它有助于直接向呼吸道输送,流感病毒主要复制.该化合物一般都具有良好的性能,安全性特征包括轻度和中度的副作用.它对各种流感菌株,包括那些耐其他抗病毒剂的菌株,具有有效作用,因此在抗病毒治疗中是一种宝贵的选择.与任何药物一样,在使用时必须考虑潜在的相互作用和反毒反应.

结构式图片

MSDS等安全信息

上下游产品

(4S,5R,6R)-5-乙酰氨基-4-胍基-6-((1R,2R)-2,3-二羟基-1-甲氧基丙基)-5,6-二氢-4H-吡喃-2-甲酸 Laninamivir 203120-17-6
(2R,3R,4S)-3-Acetamide-4-[2,3-Bis(Tert-Butoxycarbonyl)Guanidino]-2-[(1R,2R)-2,3-Dihydroxy-1-Methoxypropyl]-3,4-Dihydro-2H-Pyran-6-Carboxylic Acid
(4S,5R,6R)-5-乙酰氨基-4-氨基-6-((1R,2R)-2,3-二羟基-1-甲氧基丙基)-5,6-二氢-4H-吡喃-2-羧酸 (2R,3R,4S)-3-Acetamide-4-Amino-2-[(1R,2R)-2,3-Dihydroxy-1-Methoxypropyl]-3,4-Dihydro-2H-Pyran-6-Carboxylic Acid 475483-21-7
Methyl (2R,3R,4S)-3-Acetamide-4-Azide-2-{(S)-Methoxy[(4R)-2-Oxo-1,3-Dioxolan-4-Yl]Methyl}-3,4-Dihydro-2H-Pyran-6-Carboxylate
(3Ar,4R,7Ar)-4-[(1S)-羟基((4R)-2-氧代-1,3-二氧戊环-4-基)甲基]-2-甲基-3A,7A-二氢-4H-吡喃并[3,4-D][1,3]恶唑-6-羧酸甲酯 Methyl (3As,4R,7Ar)-4-{(S)-Hydroxy-((4R)-2-Oxo-1,3-Dioxolan-4-yl)Methyl}-2-Methyl-3A,7A-Dihydro-4H-Pyrano[3,4-D][1,3]Oxazole-6-Carboxylate 1072449-84-3
(2S,4S,5R,6R)-Benzyl 5-Acetamido-2,4-Dihydroxy-6-((1R,2R)-1,2,3-Trihydroxypropyl)Tetrahydro-2H-Pyran-1-Carboxylate 113757-75-8

合成工艺路线路线简述

    📜(4S,5R,6R)-5-乙酰氨基-4-氨基-6-((1R,2R)-2,3-二羟基-1-甲氧基丙基)-5,6-二氢-4H-吡喃-2-羧酸置于盐酸,Sodium Hydroxide体系中,用 甲醇,水 用作溶剂,化学反应 51.0H,反应生成辛酸拉尼米韦
    参考文献:一种拉尼米韦辛酸酯中间体及其制备方法
    标题:一种拉尼米韦辛酸酯中间体及其制备方法
    摘要:本发明公开了一种拉尼米韦辛酸酯中间体及其制备方法.所述拉尼米韦辛酸酯中间体12的制备方法包括如下步骤:在溶剂中,在碱的作用下,将拉尼米韦辛酸酯中间体10与化合物19进行如下反应,其中,R为甲基或乙基;X为cl,Br,I,Hso4或h2Po4.本发明的制备方法路线更短,所用试剂更经济,制备成本低,并且后处理简单,适合于工业化生产.

    海关参考信息

    专利信息


    专利号:US-2023364251-A1
    优先权日:2020-08-06
    标 题:Methods for the synthesis of protein-drug conjugates
    发明人:BORCHARDT ALLEN; HUGHES ROBERT MICHAEL
    权利人:CIDARA THERAPEUTICS INC
    摘要:The present invention relates to intermediates and methods for synthesizing protein-drug conjugates that can be used for the treatment of diseases and related conditions.

    专利号:EP-4192512-A1
    优先权日:2020-08-06
    标题 :Methods for the synthesis of protein-drug conjugates

    专利号:WO-2022032175-A1
    优先权日:2020-08-06
    标题 :Methods for the synthesis of protein-drug conjugates

    专利号:US-2023365608-A1
    优先权日:2019-02-01
    标 题 :Antiviral nucleosides and derivatives thereof
    发明人:BEIGELMAN LEONID; WANG GUANGYI; DYATKINA NATALIA
    权利人:JANSSEN BIOPHARMA INC
    摘要:Disclosed herein are nucleoside compounds and derivatives thereof, pharmaceutical compositions containing same, and their methods of synthesis. The compounds are useful in treating orthomyxovirus infections, such as influenza infections.

    专利号:CN-111116567-B
    优先权日:2013-09-09
    标题 :Intermediates of zanamivir and lanamivir and their synthesis methods

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ogawa T, Tanaka K, Ohgino K, Omori N, Betsuyaku T, Sayama K. Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases. J Infect Chemother. 2019 Dec;25(12):1043-1046. doi: 10.1016/j.jiac.2019.05.008. Epub 2019 Jun 6. 58(17):2501-2505. doi: 10.2169/internalmedicine.2740-19. Epub 2019 May 22.
    3: Tomozawa T, Hoshino K, Yamashita M, Kubo S. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus. J Infect Chemother. 2019 Aug;25(8):584-588. doi: 10.1016/j.jiac.2019.02.023. Epub 2019 Mar 29. comparison with the 2011/12 to 2015/16 seasons. J Infect Chemother. 2018 Sep;24(9):718-724. doi: 10.1016/j.jiac.2018.04.013. Epub 2018 Jun 1.
    3:26. doi: 10.1186/s40780-017-0094-7.

    合成参考文献


    摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知